Drug Trial Radar · NCT06647498
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
280
Planned (sponsor's estimate)
Start
Nov 22, 2024
Primary completion
Mar 2034
Study completion Aug 2034
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Alzheimer's Association; Eli Lilly and Company; National Institute on Aging (NIA); GHR Foundation; Private Donors
- First posted
- Oct 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remternetug. Stage 1 will determine if treatment with the study drug prevents or reverses amyloid beta (Aβ) accumulation compared with placebo in participants with dominantly inherited Alzheimer's disease (DIAD). Stage 2 will evaluate the effect of early anti-amyloid treatment on downstream biomarkers of AD in treated participants compared to external control groups.
Conditions
- Alzheimers Disease
- Dementia
- Alzheimers Disease, Familial
Interventions
RemternetugDrug
Administered subcutaneously every 12 weeks
Matching Placebo (Remternetug)Drug
Administered as subcutaneous injection of placebo every 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1: Change in amyloid load as measured by centiloid (CL) [11C]PiB-PET as biomarker endpoint for DIAN-TU-002 remternetug armTime frame: Baseline and Week 192
Locations
36 sites in 14 countries. Site status is shown where the registry gives one.
University of Alabama in Birmingham
Birmingham, Alabama · Recruiting
University of California San Diego Medical Center
La Jolla, California · Recruiting
University of Southern Califonria
Los Angeles, California · Recruiting
Yale University School of Medicine
New Haven, Connecticut · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Advocate Lutheran General Hospital
Park Ridge, Illinois · Recruiting
Indiana University School of Medicine
Indianapolis, Indiana · Recruiting
Washington University in St. Louis
St Louis, Missouri · Recruiting
New York University Medical Center
New York, New York · Recruiting
University of Pittsburgh
Pittsburgh, Pennsylvania · Recruiting
Butler Hospital
Providence, Rhode Island · Recruiting
Kerwin Research and Memory Center
Dallas, Texas · Recruiting
University of Washington
Seattle, Washington · Recruiting
Instituto de Investigaciones Neurologicas Raul Carrea, FLENI
Ciudad Autonoma de Buenos Aire, Argentina · Recruiting
Neuroscience Research Australia
Randwick, New South Wales, Australia · Recruiting
Alzheimer's Research Australia
Melbourne, Victoria, Australia · Recruiting
CHU de Quebec - Hôpital de l' Enfant Jésus
Québec, Canada · Recruiting
UBC Hospital
Vancouver, British Columbia, Canada · Recruiting
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada · Recruiting
McGill Center for Studies in Aging
Verdun, Quebec, Canada · Recruiting
Grupo de Neurociencias Sede de la Universidad de Antioquia
Medellín, Colombia · Recruiting
CHU de Toulouse - Hôpital Purpan
Toulouse, Haute Garonne, France · Not yet recruiting
Hopital Roger Salengro - CHU Lille
Lille, Nord, France · Not yet recruiting
Groupe Hospitalier Pitie-Salpetriere
Paris, Paris, France · Not yet recruiting
Hopital Neurologique Pierre Wertheimer
Bron, Rhone, France · Not yet recruiting
CHU de Rouen - Hôpital Charles Nicolle
Rouen, Seine Maritime, France · Recruiting
Universitaetsklinikum Tubingen
Tübingen, Baden-Wurttemberg, Germany · Recruiting
LMU-Campus Grosshadern
Munich, Bavaria, Germany · Recruiting
IRCCS Centro San Giovanni di Dio Fatebenefratelli
Brescia, Italy · Recruiting
Azienda Ospedaliera Universitaria Careggi
Florence, Italy · Recruiting
Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
Mexico City, Mexico City, Mexico · Not yet recruiting
New Zealand Brain Research Institute
Christchurch, New Zealand · Recruiting
University of Puerto Rico, School of Medicine
San Juan, Puerto Rico, Puerto Rico · Recruiting
Asan Medical Center
Seoul, South Korea · Not yet recruiting
Hospital Clínic I Provincial de Barcelona
Barcelona, Barcelona, Spain · Recruiting
The National Hospital for Neurology and Neurosurgery
London, Greater London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.